Rosiglitazone, unlike pioglitazone, had its routine clinical use restricted in many countries including India because of a signal for:

• A Bladder carcinoma
• B Accelerated diabetic retinopathy progression
• C Idiosyncratic fulminant hepatic failure
• D Myocardial infarction and ischemic cardiovascular events ✓

Explanation

Rosiglitazone was linked to increased myocardial infarction risk in meta-analyses, leading regulators to restrict or suspend its use, though later trials did not confirm the signal conclusively. Bladder cancer was the concern with pioglitazone, and troglitazone, not rosiglitazone, was withdrawn for fatal hepatotoxicity. Diabetic retinopathy acceleration has been reported with semaglutide, not thiazolidinediones.

Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.